Neurocrine Biosciences Inc

$106.73
(as of Apr 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Neurocrine Biosciences Inc

Stock Price
$106.73
Ticker Symbol
NBIX
Exchange
NASDAQ

Industry Information for Neurocrine Biosciences Inc

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Neurocrine Biosciences Inc

Country
USA
Full Time Employees
1,800

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Fundamentals for Neurocrine Biosciences Inc

Market Capitalization
$10,463,704,064
EBITDA
$610,099,968
Dividends per Share
P/E Ratio
32.15
Forward P/E Ratio
20.79
Earnings per Share
$3.29
Earnings per Share Estimate Next Year
Profit Margin
14.49%
Shares Outstanding
98,938,200
Percent Owned by Insiders
1.08%
Percent Owned by Institutions
99.29%
52-Week High
52-Week Low

Technical Indicators for Neurocrine Biosciences Inc

50-Day Moving Average
200-Day Moving Average
RSI
53.32
4.39

Analyst Ratings for Neurocrine Biosciences Inc

Strong Buy
15
Buy
5
Hold
4
Sell
0
Strong Sell
0

News About Neurocrine Biosciences Inc

Apr 24, 2025, 4:05 PM EST
Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern See more.
Apr 23, 2025, 7:38 AM EST
Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. See more.
Apr 22, 2025, 6:37 AM EST
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. See more.
Apr 14, 2025, 4:01 PM EST
Conference Call and Webcast Scheduled for Monday, May 5 See more.